+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Prostate Cancer Nuclear Medicine Diagnostics Market - Global Forecast 2026-2032- Product Image
Prostate Cancer Nuclear Medicine Diagnostics Market - Global Forecast 2026-2032- Product Image
New

Prostate Cancer Nuclear Medicine Diagnostics Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 196 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5639599
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Prostate Cancer Nuclear Medicine Diagnostics Market is advancing rapidly, driven by emerging molecular imaging solutions, next-generation radiopharmaceuticals, and evolving provider needs. Senior stakeholders navigating this sector face a changing technology landscape impacting both clinical and procurement strategies across varied healthcare environments.

Market Snapshot: Prostate Cancer Nuclear Medicine Diagnostics Market

The Prostate Cancer Nuclear Medicine Diagnostics Market expanded from USD 1.31 billion in 2025 to USD 1.49 billion in 2026 and is projected to reach USD 3.12 billion by 2032, at a CAGR of 13.17%. This consistent growth reflects widespread adoption of novel radiotracers, digital imaging modalities, and the increasing role of advanced diagnostics in prostate cancer management. Senior leaders are responding by evaluating technology budgets and operational planning to meet the increased demand and complexity.

Scope & Segmentation: Technologies and Markets Defined

  • Radiopharmaceutical Types: The market includes agents such as 11C Choline, 18F DCFPyL, 18F Fluciclovine, and 68Ga PSMA, with next-generation options like 18F PSMA-1007 and 64Cu PSMA entering clinical interest. Each radiotracer offers distinct imaging characteristics and influences diagnostic protocols.
  • Imaging Modalities: PET platforms, including Digital PET and Time-of-Flight PET, as well as SPECT options like Conventional SPECT and SPECT/CT, support a range of prostate cancer detection and monitoring needs, shaping both workflow and hardware investments.
  • Provider Settings: Key environments include Academic Research Institutes driving investigational use, Diagnostic Centers expanding access, and Hospitals integrating diagnostics into standard protocols. Each setting brings unique operational priorities and implementation considerations that affect technology uptake.
  • Clinical Indications: Application areas focus on Biochemical Recurrence Detection, Initial Staging, and Treatment Monitoring. These require high imaging accuracy, reliability, and the ability to standardize results across sites for consistent patient management.
  • Regional Coverage: Americas, Europe, Middle East & Africa, and Asia-Pacific each present distinct regulatory environments, supply chain structures, and adoption trajectories, requiring tailored approaches to overcome local challenges.

Key Takeaways: Strategic Insights for Senior Decision Makers

  • Molecular imaging agents and advancements in detector technology are shifting clinical procedures, improving precision in lesion localization and guiding targeted treatments.
  • The incorporation of hybrid imaging systems and AI-enabled analytics is helping standardize diagnostic interpretation and support team-based clinical decisions across the care pathway.
  • Emerging clinical and regulatory evidence underscores the need for closely coordinated engagement between payer groups, health systems, and manufacturers to define optimal patient selection and diagnostic strategies.
  • Operational models must prioritize flexible procurement, logistics, and workforce training to support consistent supply of radiopharmaceuticals and mitigate site-specific challenges.
  • Strategic partnerships with suppliers and diversified sourcing are vital to safeguard against disruptions in the nuclear medicine diagnostics supply chain, enabling successful introduction of advanced agents and technology.
  • Selecting appropriate imaging hardware and tracer chemistry is central for smooth adoption of new solutions in diverse provider settings, enabling organizations to address varied patient populations and standards of care.

Tariff Impact: Navigating Procurement Economics and Operational Continuity

Recent changes to United States tariffs have added complexity to the nuclear medicine diagnostics supply chain, resulting in higher costs for essential components and imported precursors. In response, providers are renegotiating vendor agreements, seeking alternative suppliers, and localizing certain production steps. Some organizations are implementing updated inventory management strategies to counter potential trade interruptions. These developments have elevated the priority of collaborative procurement, regional redundancy planning, and agile logistics to maintain uninterrupted diagnostic services and manage cost exposure.

Market Methodology & Data Sources

This analysis is built on comprehensive reviews of peer-reviewed studies, clinical trial data, regulatory submissions, and structured interviews with clinicians, radiopharmacists, and operational leaders. Additional context is provided by patent analysis and real-world case studies. All insights are cross-validated across multiple data streams to ensure relevance, while operational findings are normalized to give strategic clarity for executives.

Why This Report Matters: Guidance for Proactive Leadership

  • Enables evidence-based strategic planning by clarifying the impact of technological and policy shifts on evolving clinical investment and operational models in nuclear medicine diagnostics.
  • Provides procurement and executive teams with benchmarks to develop robust sourcing approaches, align with shifting regulatory frameworks, and prepare for deployment of innovative diagnostic solutions.
  • Supports provider organizations in assessing regional implementation challenges, forming strategic partnerships, and advancing workforce skills to optimize adoption of advanced diagnostic technologies.

Conclusion

The Prostate Cancer Nuclear Medicine Diagnostics Market is characterized by rapid technological evolution, dynamic supply networks, and ongoing policy refinement. Leadership teams who proactively align with these changes are positioned to support improved diagnostics and enhance value across clinical and operational settings.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Prostate Cancer Nuclear Medicine Diagnostics Market, by Radiopharmaceutical
8.1. 11C Choline
8.2. 18F DcfpyL
8.3. 18F Fluciclovine
8.4. 68Ga Psma
8.5. Emerging Agents
8.5.1. 18F Psma 1007
8.5.2. 64Cu Psma
9. Prostate Cancer Nuclear Medicine Diagnostics Market, by Modality
9.1. Pet
9.1.1. Digital Pet
9.1.2. Time Of Flight Pet
9.2. Spect
9.2.1. Conventional Spect
9.2.2. Spect Ct
10. Prostate Cancer Nuclear Medicine Diagnostics Market, by Indication
10.1. Biochemical Recurrence Detection
10.2. Initial Staging
10.3. Treatment Monitoring
11. Prostate Cancer Nuclear Medicine Diagnostics Market, by End User
11.1. Academic Research Institute
11.2. Diagnostic Center
11.3. Hospital
12. Prostate Cancer Nuclear Medicine Diagnostics Market, by Region
12.1. Americas
12.1.1. North America
12.1.2. Latin America
12.2. Europe, Middle East & Africa
12.2.1. Europe
12.2.2. Middle East
12.2.3. Africa
12.3. Asia-Pacific
13. Prostate Cancer Nuclear Medicine Diagnostics Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Prostate Cancer Nuclear Medicine Diagnostics Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. United States Prostate Cancer Nuclear Medicine Diagnostics Market
16. China Prostate Cancer Nuclear Medicine Diagnostics Market
17. Competitive Landscape
17.1. Market Concentration Analysis, 2025
17.1.1. Concentration Ratio (CR)
17.1.2. Herfindahl Hirschman Index (HHI)
17.2. Recent Developments & Impact Analysis, 2025
17.3. Product Portfolio Analysis, 2025
17.4. Benchmarking Analysis, 2025
17.5. ABX Advanced Biochemical Compounds GmbH
17.6. Bayer AG
17.7. Blue Earth Diagnostics Inc.
17.8. Bracco Imaging S.p.A.
17.9. Cardinal Health, Inc.
17.10. Curium Pharma
17.11. Eckert & Ziegler Strahlen- und Medizintechnik AG
17.12. GE HealthCare Technologies Inc.
17.13. Isotope Technologies Munich SE
17.14. Jubilant Radiopharma
17.15. Koninklijke Philips N.V.
17.16. Lantheus Holdings, Inc.
17.17. NCM-USA LLC
17.18. Novartis AG
17.19. Siemens Healthineers AG
17.20. Telix Pharmaceuticals Limited
List of Figures
FIGURE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 12. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 11C CHOLINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F DCFPYL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F FLUCICLOVINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 68GA PSMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 18F PSMA 1007, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY REGION, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY 64CU PSMA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIGITAL PET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TIME OF FLIGHT PET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY CONVENTIONAL SPECT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT CT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL RECURRENCE DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INITIAL STAGING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 68. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 90. LATIN AMERICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 99. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 101. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 102. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 103. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 104. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 105. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 106. EUROPE PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 111. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 112. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 113. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 114. MIDDLE EAST PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 115. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 117. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 118. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 119. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 120. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 121. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 122. AFRICA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 131. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 132. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 133. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 134. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 135. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 136. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 137. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 138. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 139. ASEAN PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 142. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 143. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 144. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 145. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 146. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 147. GCC PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 148. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 150. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 151. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 152. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 153. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 154. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. EUROPEAN UNION PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 157. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 158. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 159. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 160. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 161. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 162. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 163. BRICS PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 164. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 165. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 166. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 167. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 168. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 169. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 170. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 171. G7 PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 172. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 174. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 175. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 176. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 177. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 178. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 179. NATO PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 180. GLOBAL PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 182. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 183. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 184. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 185. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 186. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 187. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 188. UNITED STATES PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 189. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 190. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY RADIOPHARMACEUTICAL, 2018-2032 (USD MILLION)
TABLE 191. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY EMERGING AGENTS, 2018-2032 (USD MILLION)
TABLE 192. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
TABLE 193. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY PET, 2018-2032 (USD MILLION)
TABLE 194. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY SPECT, 2018-2032 (USD MILLION)
TABLE 195. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 196. CHINA PROSTATE CANCER NUCLEAR MEDICINE DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Prostate Cancer Nuclear Medicine Diagnostics market report include:
  • ABX Advanced Biochemical Compounds GmbH
  • Bayer AG
  • Blue Earth Diagnostics Inc.
  • Bracco Imaging S.p.A.
  • Cardinal Health, Inc.
  • Curium Pharma
  • Eckert & Ziegler Strahlen- und Medizintechnik AG
  • GE HealthCare Technologies Inc.
  • Isotope Technologies Munich SE
  • Jubilant Radiopharma
  • Koninklijke Philips N.V.
  • Lantheus Holdings, Inc.
  • NCM-USA LLC
  • Novartis AG
  • Siemens Healthineers AG
  • Telix Pharmaceuticals Limited

Table Information

Report AttributeDetails
No. of Pages196
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.12 Billion
Compound Annual Growth Rate13.1%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Nuclear Medicine Radioisotopes Market - Global Forecast 2026-2032 - Product Image

Nuclear Medicine Radioisotopes Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Nuclear Medicine Market - Global Forecast 2026-2032 - Product Image

Nuclear Medicine Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2025 - Product Image

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Nuclear Medicine Market Report and Forecast 2025-2034 - Product Image

Nuclear Medicine Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Nuclear Medicine Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From

About the Prostate Cancer Nuclear Medicine Diagnostics Market

Prostate cancer nuclear medicine diagnostics is a segment within the broader field of medical diagnostics focused on using nuclear medicine techniques to detect and evaluate prostate cancer. Nuclear medicine is a medical specialty that employs small amounts of radioactive materials, known as radiopharmaceuticals, to diagnose and sometimes treat diseases. In prostate cancer diagnosis, these radiopharmaceuticals are designed to target specific molecules associated with the presence of cancer cells, such as the prostate-specific membrane antigen (PSMA). Imaging technologies like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are utilized in conjunction with these radiotracers to visualize the distribution of the radioactive material within the prostate gland and surrounding tissues. This enables physicians to detect the presence and extent of prostate cancer, thereby guiding treatment decisions and prognostication. Key players in the prostate cancer nuclear medicine diagnostics market include companies that specialize in the production of radiopharmaceuticals, as well as those that manufacture the imaging equipment used in the diagnostic process. Some prominent companies in this market are Advanced Accelerator Applications (a subsidiary of Novartis), Blue Earth Diagnostics (a Bracco company), Progenics Pharmaceuticals (part of Lantheus Medical Imaging), IsoRay Medical, and Bayer AG. These companies engage in research and development to improve the specificity and sensitivity of nuclear diagnostic agents for prostate cancer and strive to create advanced imaging systems for more precise disease characterization. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.